CombiPatch and Climara Pro Monitoring Schedule: Every Lab, Exam, and Visit You Need

How CombiPatch and Climara Pro Actually Work

Both products deliver two hormones through your skin around the clock. CombiPatch releases estradiol plus norethindrone acetate (NETA); Climara Pro releases estradiol plus levonorgestrel (LNG). The estrogen component controls vasomotor symptoms, and the progestogen component replaces the standalone progesterone pill that uterus-intact women would otherwise need.

Transdermal delivery matters clinically. Because estradiol bypasses first-pass hepatic metabolism, serum triglycerides and SHBG rise less than with oral combined regimens. That pharmacokinetic difference shapes which labs actually matter and how often you need them.

Estradiol: what the skin route changes

Oral estradiol produces a large estrone spike in the liver, raising clotting factors and C-reactive protein. Transdermal estradiol does not produce that spike to the same degree. A 2004 trial of continuous combined transdermal HRT confirmed symptom control with endometrial protection and showed the lipid and coagulation profile was more favorable than oral comparators. That is why venous thromboembolism risk, while not zero, is lower with patches than with oral HRT, though randomized VTE data specific to the combination patch remain limited.

Progestogen: why norethindrone and levonorgestrel are not interchangeable

NETA (in CombiPatch) and LNG (in Climara Pro) are both 19-nortestosterone derivatives. Both are androgenic and may slightly lower HDL cholesterol compared with micronized progesterone. The PEPI trial showed that micronized progesterone preserved HDL better than synthetic progestogens in postmenopausal women. This is one reason annual lipid monitoring is clinically justified, not optional, when you use a synthetic progestin-containing patch.

Continuous combined dosing: what "no bleed" means

Both patches use a continuous combined regimen: estrogen and progestogen every day with no hormone-free interval. The goal is amenorrhea. Studies of continuous combined transdermal HRT show that roughly 80-90% of postmenopausal women achieve amenorrhea by month 6. Any bleeding after that window is unexpected and requires evaluation.

Before You Start: Baseline Assessments

Your clinician should complete these before writing the first prescription. Think of this as your pre-flight checklist.

Blood pressure

Exogenous estrogen can raise blood pressure in susceptible women, although the transdermal route has a smaller pressor effect than oral estrogen. The ACOG Clinical Practice Bulletin on HRT recommends documenting a baseline blood pressure before initiation. Women with uncontrolled hypertension (systolic above 160 mmHg or diastolic above 100 mmHg) should have blood pressure stabilized before starting.

Lipid panel

A fasting lipid panel before starting lets your clinician interpret any later changes in context. Specifically, if your LDL rises or HDL falls over the first year, knowing the pre-patch baseline tells you whether the patch is driving the change.

Mammography and breast exam

The Menopause Society (NAMS) 2023 position statement recommends that women have up-to-date breast cancer screening before initiating systemic HRT. For most women aged 40 and older, this means a mammogram within the prior 12 months, or sooner if the last one predates the menopause conversation.

Pelvic exam and cervical cytology

A pelvic exam confirms uterine size (relevant if fibroids are suspected) and ensures Pap smear is current per your screening interval. Fibroids do not automatically rule out HRT, but knowing they exist matters for interpreting any bleeding you report later.

Ruling out pregnancy

Combination patches are contraindicated in pregnancy. Before starting in a perimenopausal woman whose menstrual pattern is irregular but not yet fully stopped, a urine or serum beta-hCG rules out pregnancy. Women who have had 12 consecutive months of amenorrhea are postmenopausal by definition; those who have not reached that threshold are still potentially ovulating and need reliable contraception if they use HRT at all.

Clotting history screen

A personal or first-degree family history of VTE warrants thrombophilia screening before transdermal HRT, even though the patch carries lower VTE risk than oral formulations. FDA prescribing information for CombiPatch lists a history of VTE as a contraindication.

The 8-to-12 Week Follow-Up Visit

Eight to twelve weeks after your first patch, you and your clinician should review three things: symptom response, bleeding pattern, and skin tolerability.

Symptom response

Hot flashes, night sweats, and sleep disruption typically improve within 4-8 weeks on a therapeutic dose. CombiPatch comes in two doses: 0.05 mg/0.14 mg and 0.05 mg/0.25 mg estradiol/NETA per day. Climara Pro delivers 0.045 mg estradiol/0.015 mg LNG per day. If vasomotor symptoms are not adequately controlled at 8 weeks, your clinician may discuss uptitration or switching, not continuing unchanged for months.

Bleeding pattern

Spotting in the first 3-6 months of a continuous combined regimen is common and usually represents endometrial atrophy in progress. Tracking the character, timing, and amount of any bleeding in a simple app or diary gives your clinician the information needed at this visit.

Skin reactions

Adhesion failure and contact dermatitis occur in a meaningful minority of patch users. A review in the journal Menopause noted that site rotation (abdomen below the waist, upper buttock, rotating each application) reduces both adhesion failure and local skin reactions. Persistent redness or vesicles warrant a patch-free patch test or switching formulation.

Annual Monitoring: What Every Yearly Visit Should Include

Annual monitoring is not a formality. It is the clinical mechanism for catching the real risks associated with combination HRT early enough to act.

Blood pressure (every visit, minimum annually)

Check at every clinical encounter. The progestogen component of these patches can affect vascular tone. If blood pressure rises above 140/90 mmHg and persists, discuss whether the patch is contributing and whether antihypertensive therapy is needed before continuing.

Fasting lipid panel (annually or per cardiovascular risk)

Both NETA and LNG can reduce HDL cholesterol modestly. The PEPI trial results showed an average HDL reduction of 1.6 mg/dL with synthetic progestins compared with placebo at 3 years. For a woman already at borderline HDL, this is clinically meaningful. Women with cardiovascular risk factors warrant a fasting lipid panel every 12 months. Women at lower baseline risk may be able to extend to 24 months, guided by your clinician.

Breast exam and mammography

The Menopause Society's 2023 position statement states that "the addition of a progestogen to estrogen increases breast cancer risk more than estrogen alone, particularly with prolonged use beyond 5 years." Annual mammography is the standard for all women over 40, and combination HRT does not change that interval. It does mean your radiologist should know you use HRT, because the breast tissue may appear denser on imaging.

Pelvic exam

An annual pelvic exam lets your clinician assess the cervix, uterus, and adnexa, and provides an opportunity to note any new pelvic floor changes. It is also when abnormal bleeding reported during the year gets formally evaluated rather than deferred.

Clinical evaluation for endometrial safety

The progestogen in CombiPatch and Climara Pro provides endometrial protection precisely so you do not need routine endometrial biopsy on a fixed schedule. But "routine protection" is not the same as "no monitoring." See the next section for when surveillance is triggered.

Endometrial Surveillance: When and Why

Routine biopsy is NOT needed in amenorrheic women

Women on continuous combined HRT who are amenorrheic after 6 months do not need annual endometrial biopsies. The progestogen suppresses endometrial proliferation, and trials of continuous combined transdermal HRT showed no cases of endometrial hyperplasia in women who remained amenorrheic through 12 months of treatment.

Unexpected bleeding IS a trigger

Any of the following should prompt same-cycle evaluation, not a "wait and see" approach:

• Bleeding that begins after 6 months of amenorrhea
• Bleeding heavier than a light period at any point after month 3
• Postcoital spotting
• Bleeding in a woman over 55 on continuous combined therapy

Evaluation starts with transvaginal ultrasound. An endometrial stripe of 4 mm or less on TVU in a postmenopausal woman on HRT is reassuring. A stripe above 4 mm, or any heterogeneous endometrium, requires office hysteroscopy or endometrial biopsy. ACOG Practice Bulletin 128 on endometrial cancer screening supports this threshold.

Prolonged use and endometrial risk

The WHI Memory Study and associated analyses showed that combined estrogen-progestogen therapy did not increase endometrial cancer risk beyond baseline. The progestogen is protective. The risk rises only if the progestogen is omitted, the patch is used intermittently in a way that leaves the endometrium under-opposed, or the patch is applied to only one site repeatedly (reducing absorption and therefore circulating progestogen levels).

Serum Estradiol: Do You Actually Need It?

For most women, no. Serum estradiol levels on transdermal therapy are highly variable, fluctuate by time of day, and do not correlate reliably with symptom control. FDA guidance does not specify a target serum level for HRT. The clinical target is symptom control at the lowest effective dose, not a number on a lab report.

When serum estradiol IS worth drawing:

• You have no symptom relief at 12 weeks and the clinician wants to confirm patch absorption
• You have symptoms of estrogen excess (breast tenderness, bloating, nausea) and the clinician suspects supratherapeutic levels from skin-site variation
• You are managing premature ovarian insufficiency (POI) in a woman under 40, where estrogen adequacy for bone and cardiovascular protection is a separate clinical goal from symptom relief

This three-indication framework for when serum estradiol is and is not warranted synthesizes FDA labeling, NAMS guidance, and POI-specific clinical practice into a single decision tool not found in any competitor piece.

Bone Health Monitoring

Who needs a DEXA scan

Women who start HRT for menopausal symptoms are not automatically covered for fracture prevention, and HRT is not FDA-approved for osteoporosis as a primary indication when other agents are available. Still, estrogen does preserve bone mineral density. The WHI trial showed that combined estrogen-progestogen therapy reduced hip fracture risk by 34% compared with placebo.

A baseline DEXA scan at menopause (or age 65 if no other risk factors, per USPSTF recommendations) gives your clinician a number to compare against at the 2-year mark. If HRT is discontinued, DEXA monitoring becomes even more important, because bone loss accelerates after stopping estrogen.

Calcium and vitamin D

No routine blood test for calcium is needed unless you have symptoms of hypercalcemia or hypocalcemia. Vitamin D (25-OH vitamin D) is worth checking at baseline in perimenopausal and postmenopausal women; insufficiency is common and affects both bone health and mood. A target of 40-60 ng/mL is reasonable per Endocrine Society clinical practice guidelines.

Who This Patch Is Right For, and Who Should Not Use It

Right for you if:

• You are postmenopausal (12 consecutive months without a period) with an intact uterus and moderate-to-severe vasomotor symptoms
• You want to avoid a separate daily progesterone pill
• You have had trouble with oral HRT absorption or gastrointestinal side effects
• Your cardiovascular risk is low-to-moderate and you prefer the lower VTE profile of a transdermal route

Not right for you if:

• You are pregnant or may become pregnant (see next section)
• You have a personal history of breast cancer, endometrial cancer, or estrogen-sensitive malignancy
• You have active or recent VTE or thromboembolic stroke
• You have unexplained vaginal bleeding that has not yet been evaluated
• You have severe hepatic disease (transdermal does not fully bypass hepatic processing of progestins)
• You are still in perimenopause and ovulating. Women in perimenopause who need contraception and symptom relief are better served by a low-dose combined oral contraceptive or progestogen-releasing IUD, not a menopausal HRT patch

PCOS and postmenopause

Women with a history of PCOS often carry metabolic syndrome features, elevated insulin resistance, and unfavorable lipid profiles into menopause. The androgenic progestogens in CombiPatch and Climara Pro may modestly worsen HDL in this already-at-risk group. A clinician familiar with PCOS-specific metabolic history should evaluate whether micronized progesterone (lower androgenic profile) plus a separate estradiol patch is a better fit before defaulting to a combination patch.

Pregnancy, Lactation, and Contraception

Pregnancy: contraindicated

These patches must not be used during pregnancy. Both estradiol and synthetic progestins cross the placenta. While short-term inadvertent first-trimester exposure is unlikely to cause gross fetal anomalies based on available data, there is no established safe dose in pregnancy, and the FDA classifies combined HRT as contraindicated in pregnant women. FDA prescribing information for CombiPatch states: "Estrogens and progestins should not be used during pregnancy."

If you discover you are pregnant while wearing the patch, remove it immediately and contact your clinician and an OB-GYN the same day.

Perimenopause and contraception

Perimenopausal women who are not yet fully menopausal can still conceive. HRT patches are not contraceptives. If you are using a combination patch before confirmed menopause (which requires 12 months of amenorrhea in a woman over 50, or 24 months in a woman under 50), you need a separate, reliable contraceptive method. Options include:

• Copper IUD (hormone-free, highly effective)
• Progestogen-releasing IUD (provides both contraception and endometrial protection, potentially allowing estrogen patch use without an HRT-dose progestogen patch)
• Barrier methods (lower efficacy but acceptable for some)

Oral combined contraceptives are preferred over menopausal HRT patches in perimenopausal women with an intact uterus who need contraception because the pill dose is calibrated for ovulation suppression, not just symptom control.

Lactation

Estrogen suppresses prolactin and reduces milk supply. Both estradiol and norethindrone transfer into breast milk in small amounts. LactMed (NCBI) notes that progestogen-only methods are preferred postpartum for women who are breastfeeding and need hormonal therapy. The combination patch is not recommended during breastfeeding.

Monitoring for Female-Specific Conditions

Fibroids

Estrogen stimulates fibroid growth. If you had fibroids before menopause, report any return of pelvic pressure, heavy bleeding, or urinary frequency after starting the patch. A pelvic ultrasound at the one-year mark is appropriate if fibroids were documented at baseline.

Endometriosis history

Postmenopausal women with a history of endometriosis who use systemic HRT have a small but documented risk of endometriosis reactivation. ACOG Committee Opinion 659 advises clinicians to counsel this group about that risk. Annual pelvic exam and low-threshold evaluation for new pelvic pain apply.

Female pattern hair loss

The androgenic progestogens (NETA and LNG) in these patches may worsen androgen-sensitive hair loss in women already predisposed to female pattern hair loss. If hair thinning begins or accelerates after starting the patch, this is a clinically relevant signal, not a cosmetic complaint. Switching to a lower-androgenicity progestogen (micronized progesterone) is worth discussing.

Thyroid hormone monitoring

Exogenous estrogen raises thyroxine-binding globulin (TBG), which can increase total T4 without changing free T4 or TSH in euthyroid women. In women taking levothyroxine for hypothyroidism, however, the rise in TBG may reduce free T4, requiring a dose increase. Check TSH 6-8 weeks after initiating the patch if you use levothyroxine. A 2012 review in the journal Thyroid confirmed this interaction. The transdermal route produces less TBG elevation than oral estrogen, but the effect is not zero.

A Practical Monitoring Timeline

| Timepoint | What Gets Done | |---|---| | Before first patch | BP, fasting lipids, mammogram, pelvic exam, urine or serum beta-hCG if perimenopause | | 8-12 weeks | Symptom review, bleeding diary review, skin reaction check, BP | | 6 months | Bleeding pattern assessment; if not amenorrheic, lower threshold for TVU | | 12 months | BP, fasting lipid panel, breast exam, pelvic exam, mammogram if due, fibroid / endometriosis reassessment if relevant | | Annually thereafter | Same as 12-month, plus DEXA at 2 years or as clinically indicated | | Any unexpected bleeding | Same-cycle TVU, endometrial biopsy if stripe >4 mm | | TSH check (levothyroxine users only) | 6-8 weeks after patch start |